Testing personalized therapy for advanced cancer patients with fluid buildup

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of patient-derived tumor-like cell clusters (PTC) drug sensitivity testing in predicting clinical outcomes for patients with advanced malignancies such as lung, breast, gastric, and colorectal cancers. It plans to enroll 55 patients who will undergo PTC drug screening using fresh malignant effusion samples. Based on the screening results, patients will receive two cycles of personalized therapy, allowing researchers to assess the correlation between drug sensitivity results and actual treatment outcomes. The study seeks to enhance the precision of cancer treatment by tailoring therapies to individual patient profiles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18 to 75 years old, regardless of gender.
2. Score of nutrition risk screening 2002 (NRS2002) is less than 3, NRS20023.
3. Advanced and unresectable malignancy confirmed by biopsy diagnosis.
4. Able to tolerate anti-tumor treatment, and without serious cardiopulmonary and other underlying diseases.
5. Score of eastern cooperative oncology group (ECOG) is not higher than 2, ECOG≤2.
6. Anticipated survival exceed six months.
7. At least one measurable lesions (according to RECIST 1.1)
8. Resistance or intolerance to standard therapy regimens.
9. Signed informed consent form voluntarily.

Exclusion Criteria:

1. Pregnant or lactating women.
2. Have Participated other clinical trials in six months.
3. Severe liver dysfunction.
4. Severe renal dysfunction.
5. Patients with cognitive disorder, mental diseases and terrible compliance.
6. Allergic to known chemotherapeutic agents.
7. Other circumstance not suitable to participate in this trial determined by investigators.

Where it's running

• Tongji Hospital
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Liu Huang — Tongji Hospital
• Study coordinator: Liu Huang
• Email: huangliu@tjh.tjmu.edu.cn
• Phone: 63639656

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Combination therapy using checkpoint inhibitors for advanced solid tumors

  This study is testing a new combination treatment using special antibodies for people with advanced solid tumors like lung and liver cancer to see if it can be safer and more effective than current options.

  Recruiting Phase 1/2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05187338

• Evaluating progastrin levels in cancer patients

  This study is testing if measuring progastrin levels in the blood can help predict how cancer will progress and respond to treatment in patients with different types of cancer.

  Recruiting at 17 sites Hospices Civils de Lyon · Bron and 16 other locations · NCT03787056

• Combining a special virus with immune cells to treat advanced HER2 positive cancers

  This study is testing a new treatment that combines a special virus and immune cells to see if it can help people with advanced HER2 positive cancers.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT03740256

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.